4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
New Ray Medicine International Holding Limited (6108) operates in the Pharmaceutical Retailers industry and is headquartered in Hangzhou, China with about 31 employees. Its market capitalization is roughly HKD 41 million. In the fiscal year ended 2025-12-31, 6108 reported HKD 130M in revenue and (HKD 20M) in net income.
New Ray Medicine International Holding Limited, an investment holding company, engages in distribution and trading of pharmaceutical and related products in the People's Republic of China.
Interactive charts & full statements →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | HKD 130M | HKD 94M | HKD 50M | HKD 90M | — |
| Gross Profit | HKD 16M | HKD 12M | HKD 13M | HKD 13M | — |
| Operating Income (EBIT) | (HKD 8M) | (HKD 19M) | (HKD 16M) | (HKD 26M) | — |
| Net Income | (HKD 20M) | (HKD 31M) | (HKD 22M) | (HKD 78M) | — |
HKD; HKDM / HKDB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | HKD 436M | HKD 505M | HKD 492M | HKD 540M | — |
| Total Liabilities | HKD 12M | HKD 34M | HKD 11M | HKD 14M | — |
HKD; HKDM / HKDB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive 6108 viewer.
About TickerBase · Data methodology & sources · Privacy · Terms